These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 29428719

  • 1. Combination effects of alogliptin and pioglitazone on steatosis and hepatic fibrosis formation in a mouse model of non-alcoholic steatohepatitis.
    Amano Y, Tsuchiya S, Imai M, Tohyama K, Matsukawa J, Isono O, Yasuno H, Enya K, Koumura E, Nagabukuro H.
    Biochem Biophys Res Commun; 2018 Feb 26; 497(1):207-213. PubMed ID: 29428719
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes.
    Scheen AJ.
    Expert Opin Drug Metab Toxicol; 2015 Jun 26; 11(6):1005-20. PubMed ID: 25936384
    [Abstract] [Full Text] [Related]

  • 3. Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment.
    Triplitt C, Cersosimo E, DeFronzo RA.
    Vasc Health Risk Manag; 2010 Sep 07; 6():671-90. PubMed ID: 20859539
    [Abstract] [Full Text] [Related]

  • 4. Thiazolidinediones improve hepatic fibrosis in rats with non-alcoholic steatohepatitis by activating the adenosine monophosphate-activated protein kinase signalling pathway.
    Zhang W, Wu R, Zhang F, Xu Y, Liu B, Yang Y, Zhou H, Wang L, Wan K, Xiao X, Zhang X.
    Clin Exp Pharmacol Physiol; 2012 Dec 07; 39(12):1026-33. PubMed ID: 23127227
    [Abstract] [Full Text] [Related]

  • 5. [A compounding agent of alogliptin and pioglitazone].
    Ueki K.
    Nihon Rinsho; 2011 May 07; 69(5):877-82. PubMed ID: 21595275
    [Abstract] [Full Text] [Related]

  • 6. The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice.
    Moritoh Y, Takeuchi K, Asakawa T, Kataoka O, Odaka H.
    Eur J Pharmacol; 2009 Jan 14; 602(2-3):448-54. PubMed ID: 19038243
    [Abstract] [Full Text] [Related]

  • 7. Alogliptin alleviates hepatic steatosis in a mouse model of nonalcoholic fatty liver disease by promoting CPT1a expression via Thr172 phosphorylation of AMPKα in the liver.
    Tobita H, Sato S, Yazaki T, Mishiro T, Ishimura N, Ishihara S, Kinoshita Y.
    Mol Med Rep; 2018 May 14; 17(5):6840-6846. PubMed ID: 29512720
    [Abstract] [Full Text] [Related]

  • 8. Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants.
    Karim A, Laurent A, Munsaka M, Wann E, Fleck P, Mekki Q.
    J Clin Pharmacol; 2009 Oct 14; 49(10):1210-9. PubMed ID: 19622714
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.
    DeFronzo RA, Burant CF, Fleck P, Wilson C, Mekki Q, Pratley RE.
    J Clin Endocrinol Metab; 2012 May 14; 97(5):1615-22. PubMed ID: 22419732
    [Abstract] [Full Text] [Related]

  • 10. Acetyl-CoA carboxylase 1 and 2 inhibition ameliorates steatosis and hepatic fibrosis in a MC4R knockout murine model of nonalcoholic steatohepatitis.
    Matsumoto M, Yashiro H, Ogino H, Aoyama K, Nambu T, Nakamura S, Nishida M, Wang X, Erion DM, Kaneko M.
    PLoS One; 2020 May 14; 15(1):e0228212. PubMed ID: 31990961
    [Abstract] [Full Text] [Related]

  • 11. Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats.
    Hayashizaki-Someya Y, Kurosaki E, Takasu T, Mitori H, Yamazaki S, Koide K, Takakura S.
    Eur J Pharmacol; 2015 May 05; 754():19-24. PubMed ID: 25701721
    [Abstract] [Full Text] [Related]

  • 12. Administration of pioglitazone alone or with alogliptin delays diabetes onset in UCD-T2DM rats.
    Cummings BP, Bettaieb A, Graham JL, Stanhope K, Haj FG, Havel PJ.
    J Endocrinol; 2014 Apr 05; 221(1):133-44. PubMed ID: 24627447
    [Abstract] [Full Text] [Related]

  • 13. Therapeutic effects of the dipeptidyl peptidase-IV inhibitor, sitagliptin, on non-alcoholic steatohepatitis in FLS-ob/ob male mice.
    Onoyama T, Koda M, Okamoto T, Kishina M, Matono T, Sugihara T, Murawaki Y.
    Mol Med Rep; 2015 Nov 05; 12(5):6895-902. PubMed ID: 26397061
    [Abstract] [Full Text] [Related]

  • 14. Impact of alogliptin and pioglitazone on lipid metabolism in islets of prediabetic and diabetic Zucker Diabetic Fatty rats.
    Cai Y, Lydic TA, Turkette T, Reid GE, Olson LK.
    Biochem Pharmacol; 2015 May 01; 95(1):46-57. PubMed ID: 25801003
    [Abstract] [Full Text] [Related]

  • 15. Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet.
    Kawaguchi K, Sakaida I, Tsuchiya M, Omori K, Takami T, Okita K.
    Biochem Biophys Res Commun; 2004 Feb 27; 315(1):187-95. PubMed ID: 15013444
    [Abstract] [Full Text] [Related]

  • 16. Pioglitazone suppresses inflammation and fibrosis in nonalcoholic fatty liver disease by down-regulating PDGF and TIMP-2: Evidence from in vitro study.
    Deng W, Meng Z, Sun A, Yang Z.
    Cancer Biomark; 2017 Dec 06; 20(4):411-415. PubMed ID: 28946547
    [Abstract] [Full Text] [Related]

  • 17. Enhancing pancreatic Beta-cell regeneration in vivo with pioglitazone and alogliptin.
    Yin H, Park SY, Wang XJ, Misawa R, Grossman EJ, Tao J, Zhong R, Witkowski P, Bell GI, Chong AS.
    PLoS One; 2013 Dec 06; 8(6):e65777. PubMed ID: 23762423
    [Abstract] [Full Text] [Related]

  • 18. Alogliptin alleviates liver fibrosis via suppression of activated hepatic stellate cell.
    Zhang H, Sun D, Wang G, Cui S, Field RA, Li J, Zang Y.
    Biochem Biophys Res Commun; 2019 Apr 02; 511(2):387-393. PubMed ID: 30797555
    [Abstract] [Full Text] [Related]

  • 19. The Ethanol Extract from Lonicera japonica Thunb. Regresses Nonalcoholic Steatohepatitis in a Methionine- and Choline-Deficient Diet-Fed Animal Model.
    Tzeng TF, Tzeng YC, Cheng YJ, Liou SS, Liu IM.
    Nutrients; 2015 Oct 21; 7(10):8670-84. PubMed ID: 26506376
    [Abstract] [Full Text] [Related]

  • 20. Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes.
    Bril F, Kalavalapalli S, Clark VC, Lomonaco R, Soldevila-Pico C, Liu IC, Orsak B, Tio F, Cusi K.
    Clin Gastroenterol Hepatol; 2018 Apr 21; 16(4):558-566.e2. PubMed ID: 29223443
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.